FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to antisense compounds, and can be used in medicine. The invention makes it possible to obtain an antisense oligonucleotide that can specifically inhibit the expression of apolipoprotein (apo (a)).
EFFECT: invention may be applicable in the prevention or treatment of inflammatory, cardiovascular and/or metabolic diseases, disorders or other conditions associated with apo (a) or Lp (a).
24 cl, 13 ex, 65 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATION OF FACTOR 11 EXPRESSION | 2014 |
|
RU2739594C2 |
| COMPOSITION FOR MODULATION OF C90RF72 EXPRESSION | 2014 |
|
RU2748426C2 |
| MODULATION OF PREKALLIKREIN (PKK) EXPRESSION | 2014 |
|
RU2712559C2 |
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
| METHODS AND COMPOSITIONS FOR MODELING EXPRESSION OF APOLIPOPROTEIN (A) | 2013 |
|
RU2624028C2 |
| COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2015 |
|
RU2734658C2 |
| COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | 2016 |
|
RU2736574C2 |
| COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION | 2014 |
|
RU2782034C2 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| COMPOSITIONS FOR MODULATING TAU PROTEIN EXPRESSION | 2014 |
|
RU2735551C2 |
